• Fri frakt över 249 kr
  • •
  • Snabba leveranser
  • •
  • Billiga böcker
Kundservice

Du är på sajten för privatpersoner.

Företag, bibliotek eller offentlig verksamhet?

Du handlar på classic.bokus.com, där alla dina funktioner finns intakta.
Till classic.bokus.com
Bokus logotyp. Gå till startsidan.
  • Erbjudanden
  • Nyheter
  • Student
  • Topplistor
  • Barn & ungdom
  • Bokus Play
  • E-böcker
  • Pocketböcker
  • Spel & pussel

10% rabatt på allt med kod: NYSTART10 →

Sidfot

Mina sidor

    Hjälp

    • Kundservice
    • Vanliga frågor och svar
    • Frakt och leverans
    • Retur vid ångerrätt
    • Reklamera vara
    • Betalning
    • Köpvillkor
    • Allmänna villkor
    • Information om webbplatsens tillgänglighet

    Om Bokus

    • Om oss
    • Pressrum
    • För studenter
    • För företag
    • För bibliotek och offentlig verksamhet
    • För leverantörer
    • Hållbarhet

    Populärt

    • Aktuella erbjudanden
    • Presentkort
    • Studentlitteratur
    • Nya böcker
    • Topplistor
    • Signerade böcker
    • Engelska böcker

    Inspiration

    • Boktips
    • BookTok
    • Populära bokserier
    • Barnbokskaraktärer
    • Populära författare
    Logotyp för Bokus
    Följ oss på Facebook (extern länk)Följ oss på Instagram (extern länk)Följ oss på YouTube (extern länk)Följ oss på TikTok (extern länk)
    bokus @ CookiesAnpassa cookiesIntegritetspolicyKöpvillkor
    Till Citymail hemsida (extern länk)Till Budbee hemsida (extern länk)Till Postnord hemsida (extern länk)Till Schenker hemsida (extern länk)Till Early Bird hemsida (extern länk)Till Walleys hemsida (extern länk)
    1. Medicin
    2. Andra medicinska specialiteter
    3. Farmakologi

    New Therapeutic Agents in Thrombosis and Thrombolysis

    AvJane E. Freedman,Joseph Loscalzo

    Inbunden, Engelska, 2009

    1 445 kr

    Beställningsvara. Skickas inom 3-6 vardagar. Fri frakt över 249 kr.

    Beskrivning

    As the number of patients with thrombosis and thrombolysis increases, there is a critical need for clinicians to learn the latest scientific discoveries and treatment options. This timely Third Edition is a comprehensive text for cardiologists, hematologists, and pharmacologists in need of a resource on current agent development technology for treating cardiovascular and thromboembolic diseases.New to the Third Edition:a thorough examination of all the agents involved in treating thrombosischapters on biomarkers, testing, and pharmacogenomicskey topics, including new targets for antithrombotics, the development of novel classes of platelet inhibitors, new thrombolytic therapies, and evolving clinical uses of thrombolytics for ischemic stroke and venous thrombosisthe hemostatic and thrombotic pathways

    Produktinformation

    • Utgivningsdatum:2009-06-24
    • Mått:178 x 254 x undefined mm
    • Vikt:1 360 g
    • Format:Inbunden
    • Språk:Engelska
    • Antal sidor:712
    • Upplaga:3
    • Förlag:Taylor & Francis Inc
    • ISBN:9781420069235

    Utforska kategorier

    • Farmakologi inom Medicin
    • Hjärt- och kärlsjukdomar inom Medicin
    • Hematologi inom Medicin

    Mer om författaren

    Jane E. Freedman, Joseph Loscalzo

    Recensioner i media

    "…Full of important information… is a definite addition to the medical literature." —Doody’s Reviews (for the Second Edition)

    Innehållsförteckning

    • Preface. Part I. Overview. Overview of Hemostasis and Fibrinolysis. Overview of Platelet-dependent Thrombosis. Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents. Pharmacogenomics of Anticoagulation. Pharmacogenomics of Antithrombotics. The Role of Biomarkers in the Development of Antithrombotics and Fibrinolytics. The Role of Platelet Function Testing in the Development of Platelet Inhibitors. The Role of Proteomics and Transcriptomics in the Development of Antithrombotics. Part II: New Heparins, Thrombin Inhibitors, and Antithrombotics. Overview of New Anticoagulant Drugs. Low-Molecular-Weight Heparins in Acute Coronary Syndromes. Low-Molecular-Weight Heparin Use in Pregnancy. Antithrombotic Therapy and Cancer. Prophylaxis with Low-Molecular-Weight Heparin in the Treatment of Venous Thromboembolism. Low-Molecular-Weight Heparin in the Pediatric Population. New Indications for Low-Molecular-Weight Heparins. Drugs Indicated for HIT. Hirudin for Acute Coronary Syndromes. Oral-Direct Thrombin Inhibitors: dibigatran and ximelagatran. Oral direct Factor Xa inhibitors: including rivaroxaban, apixaban, YM-150, Du-176b. Orally Active Heparin. Tissue Factor Pathway Inhibitor: (Potential Implications in the Treatment of Cardiovascular Disorders). Modulation of the Protein C Pathway as a Therapy for Thrombosis. Soluble Thrombomodulin. Activated Factor X Agonists and the Development of Synthetic Pentasaccharides: Fondaparinux and idraparinux. Factor IXa Inhibitors. Aptamers. Part III: New Antiplatelet Agents. Overview: Antiplatelet Therapy. Intravenous Glyoprotein IIb/IIIa Receptor Antagonists. Procoagulant Activities of Glycoprotein IIb/IIIa Receptor Blockers. Inhibitors of Platelet Adhesion:vWF-GP1b/IX and Collagen-GPVI inhibitors. Thienopyridines: Ticlopidine and Clopidogrel. New Thienopyridines; reversible P2Y(12) antagonists, cangrelor and AZD6140. Oral Antiplatelet Therapies Beyond Aspirin and Thienopyridines. PAR1 Inhibitors. NO donors as Platelet Inhibitors. Part IV: New Thrombolytic Agents and Indications. Overview of Established and New Thrombolytics. Thrombolysis of Deep Vein Thrombosis. Thrombolysis for Pulmonary Embolism. Thrombolysis for Ischemic Stroke. Thrombolysis for Acute Myocardial Infarction. Thrombolysis and Ultrasound. Epilogue: The Management of Thrombotic and Cardiovascular Disorders in the 21st Century.